课题基金 / 基金详情

Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models

Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models
治疗套细胞淋巴瘤的精准方法:整合基于多组学的模型
批准号:
10530111
负责人:
Holly Ann Hill
金额:
$3.47万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-01 至 2023-05-31
关键词:
AffectAgeAlcohol consumptionAreaBiologicalBiological AssayCCND1 geneCDKN2A geneCancer PatientCharacteristicsClinicalClinical ResearchComputer softwareComputing MethodologiesCorrelative StudyDNADNA sequencingDataData SetDatabasesDiagnosticDiseaseDisease ProgressionDisease stratificationDrug TargetingEnvironmental ExposureEpigenetic ProcessFrequenciesFunctional disorderGene ExpressionGene Expression ProfileGenesGenetic HeterogeneityGenetic TranscriptionGenomeGenomic InstabilityGenomicsGleanHematopoiesisHollyIndividualInvestigationKnowledgeLaboratoriesLinkMalignant NeoplasmsMantle Cell LymphomaMeasurementMeta-AnalysisMethodsModelingMolecularMolecular AbnormalityMorphologyMutateMutationMutation AnalysisNOTCH1 geneNon-Hodgkin&aposs LymphomaOther GeneticsOutcomeOutputPathway AnalysisPathway interactionsPatientsPatternPharmaceutical PreparationsPhasePrecision Medicine InitiativePrecision medicine trialPrevalencePrincipal Component AnalysisPrognosisRaceRadiation exposureRelapseReportingResearchResearch Project GrantsResistanceSample SizeSamplingSingle Nucleotide PolymorphismSmokingStatistical ModelsTP53 geneTechniquesThe Cancer Genome AtlasTranslatingUniversity of Texas M D Anderson Cancer CenterVariantanalytical methodbasecancer typecircular RNAclinical investigationclinically relevantcomplex biological systemscomputerized toolsdifferential expressionepigenomicsexome sequencingfeature selectiongenetic analysisgenome sequencingimprintindividual patientinnovationinsightlifestyle factorsliquid biopsymultiple omicsmutational statusnext generation sequencingnovelpersonalized approachpersonalized medicinepersonalized therapeuticpre-doctoralprognosticprognostic of survivalresponsesexsurvival outcometargeted treatmenttherapy resistanttranscriptome sequencingtranscriptomicstreatment responsetumor DNAtumor microenvironmentwhole genome

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary Mantle cell lymphoma (MCL) is a rare, incurable form of non Hodgkin lymphoma which is disposed to therapeutic resistance and relapse. Though rare, MCL is both clinically and genetically heterogenous and represented by multiple subtypes. It is presently unknown how various genomic features impact the clinical course of MCL and how these biological aspects contribute to treatment resistance and disease progression. It is difficult to study the molecular features of MCL due to its rarity and lack of representation in accessible databases like the cancer genome atlas (TCGA). Additionally, it is currently challenging to integrate -omics features in precision medicine initiatives due to the vast size of data from sequencing and unclear biological and clinical relevance of singular mutational and transcriptional features. It is also difficult to study these features in combination with demographic and other relevant individual features. In the F99 phase of the proposed dissertation research project, Holly Hill will employ novel analytical and computational methods to integrate multi-omics datasets in a pooled analysis of MCL patients. These analyses will include genomics, transcriptomics, epigenomics and features of the clinical exposome. Feature selection and variable reduction techniques will be used as appropriate. These sub-analyses will identify biological correlates and generate composite variables which will be used in univariate and multivariate models to examine clinical outcomes in MCL including drug response and survival. The KOO phase of the proposed activities will include further investigations into MCL and other cancers utilizing knowledge gained from the dissertation project (F99). Insights acquired during the F99 phase will also be used to develop targeted assays that simplify the mutational or transcriptional profiles of MCL into clinically useful and valid applications. Serial -omics measurements will be integrated into correlative genomics studies and precision medicine trials which will include sequencing from liquid biopsies or circulating tumor DNA (ctDNA). The proposed efforts will produce insights into condensing and translating data from -omics studies into the clinical space. It is hoped that the findings of this study will inform methods suitable for precision medicine trials and help achieve our long-term objective to personalize therapeutics for individual cancer patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: